• Parathyroid hormone (1-34) (human) in Kidney Models

  2026-09-11

  Use the PTH (1-34) peptide fragment to connect receptor-level cAMP assays with spatially organized kidney assembloid and bone metabolism research. This workflow emphasizes dose-resolved signaling, compartment-aware readouts, and troubleshooting for calcium homeostasis and osteoporosis model studies.

• Amphotericin B: Mechanism and Research Workflow

  2026-09-10

  Amphotericin B is a polyene antifungal antibiotic that targets fungal membrane sterols and disrupts ion homeostasis. This research-focused guide connects its antifungal activity, immune signaling, biofilm-resistance context, and product-specific handling parameters.

• BMS-777607 Workflows for MET Signaling Research

  2026-09-10

  BMS-777607 supports controlled MET-family inhibition in metastatic cancer models and offers a carefully bounded way to interrogate kinase signaling during hiPSC-derived megakaryocyte research. This guide combines product handling, assay design, reference-study context, and troubleshooting so researchers can distinguish validated use cases from exploratory applications.

• Porcupine Inhibition for Severe Sclerosteosis

  2026-09-09

  The reference study identifies PORCN inhibition with LGK974 as a pharmacological strategy for reducing excessive Wnt-driven bone formation in Sost-deficient mice. Its combination of osteoblast, osteoclast, gene-expression, microcomputed tomography, and mechanical-loading analyses provides a useful framework for evaluating treatments for severe sclerosteosis while highlighting sex-dependent responses and important translational limitations.

• Better In Vitro Drug Response Metrics in Cancer

  2026-09-09

  Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent components of an anticancer response. Its central methodological implication is that cancer research workflows should define, measure, and interpret proliferation arrest and cell killing separately rather than treating one viability value as a complete description of drug activity.

• Anlotinib Hydrochloride in Translational Angiogenesis

  2026-09-08

  An evidence-led analysis of how Anlotinib hydrochloride connects multi-target kinase biology with practical angiogenesis workflows, comparative research strategy, and translational decision-making in cancer research.

• Indometacin and COX-2 in Pancreatic Stellate Cells

  2026-09-08

  The reference study shows that indometacin suppresses human pancreatic stellate cell viability, migration, and activation while reducing COX-2 expression. Its main contribution is to position COX-2-dependent stromal remodeling as a pharmacologically tractable component of pancreatic ductal adenocarcinoma biology, while also defining practical readouts for cell-based validation.

• Chenodeoxycholic Acid in FXR Renal Models

  2026-09-07

  Chenodeoxycholic Acid (CDCA) connects bile acid metabolism with FXR-driven transcriptional control in renal injury models. This guide translates the FXR–KLF11 finding into practical cell, reporter, ChIP, and troubleshooting workflows while keeping preclinical limitations explicit.

• Ferrostatin-1 (Fer-1) in Ferroptosis Assays

  2026-09-07

  Ferrostatin-1 (Fer-1) provides a practical rescue control for testing iron-dependent lipid peroxidation across cell-injury models. This guide translates recent facial nerve repair research into reproducible assay setup, formulation comparisons, and troubleshooting decisions for cancer biology research and neurodegenerative disease models.

• Firefly Luciferase mRNA for Translational Insight

  2026-09-05

  A mechanistic and strategic guide to using Firefly Luciferase mRNA (ARCA, 5-moUTP) as a reproducible reporter for gene expression assays, cell viability studies, delivery benchmarking, and in vivo imaging.

• Neticonazole Hydrochloride: Evidence by Assay

  2026-09-04

  Neticonazole Hydrochloride is an imidazole antifungal with a clinically established topical role and a separate, preclinical oncology research profile. This article maps its evidence to diagnostic, antifungal, exosome, and apoptosis assays while clarifying translational limits.

• Doxycycline in AAA Research: Assay Design Guide

  2026-09-04

  Doxycycline is more than a tetracycline antibiotic in abdominal aortic aneurysm research. This assay-focused guide explains how to separate antimicrobial, metalloproteinase, oxidative-stress, and delivery effects for more interpretable preclinical experiments.

• Prochlorperazine: A Translational Melanoma Thesis

  2026-09-03

  Prochlorperazine is best understood not as a repurposing shortcut, but as a testable translational hypothesis linking dopamine D2 receptor antagonism, melanoma cell-state biology, and clinically familiar pharmacology. This article interprets the anchor study, proposes a disciplined validation strategy, and defines the boundaries between melanoma research, antiemetic therapy, and antiviral investigation.

• GPNMB Model Predicts Immunotherapy Response in ESCC

  2026-09-03

  The reference study identifies circulating soluble GPNMB as a mechanistic and clinically useful marker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors develop a multimodal model that connects tumor–immune biology with response and survival prediction.

• Staurosporine and the TBXA2R–ERM Metastasis Axis

  2026-09-02

  A translational perspective on how Staurosporine can interrogate kinase-dependent motility, invasion, apoptosis, and angiogenesis while clarifying the TBXA2R–ERM pathway identified in triple-negative breast cancer.

8057 records 4/538 page Previous Next 12345 下5页 Last page